NATIONAL INSTITUTE FOR PUBLIC HEALTH

Their core work

Cambodia's National Institute for Public Health (NIPH) is the country's primary public health research and implementation body, providing in-country scientific capacity and local population access for health intervention trials and program evaluations. In H2020 projects, they have served as the Southeast Asian implementation partner — contributing to both non-communicable disease management and women's cancer screening programs in real-world, resource-limited settings. Their core value to international consortia is on-the-ground access to Cambodian health facilities, communities, and patient populations, combined with expertise in adapting health interventions to low-income country contexts. They bridge global health research designs and local rollout realities, making them a critical link between protocol development and real-world evidence generation.

What they specialise in

How they've shifted over time

NIPH's two H2020 projects show a shift from integrated chronic disease management toward infectious disease-linked cancer prevention. Their earlier engagement (SCUBY, starting 2019) was centered on scaling up care packages for diabetes and hypertension in vulnerable groups — a focus on multimorbidity and care delivery systems. By 2021, with CHILI, the focus moved toward cervical cancer, HPV screening technology, and diagnostic methods like proteomics and point-of-care genotyping, signaling a move into oncology prevention and molecular diagnostics within community settings. The trajectory suggests NIPH is expanding its role from health system strengthening into disease-specific early detection programs, likely following Cambodia's national cancer control priorities.

NIPH is moving toward evidence-based cancer screening programs using point-of-care and molecular diagnostics, making them a relevant partner for consortia targeting low-income country implementation of diagnostic or preventive health technologies.

How they like to work

NIPH has participated exclusively as a consortium partner — never as coordinator — across both H2020 projects, suggesting they operate as a specialist implementation node rather than a project-leading body. With 15 unique partners across 10 countries from just 2 projects, they work in medium-to-large international consortia, consistent with global health research that requires multi-country evidence. Their profile suggests they are sought out for their in-country access and implementation capacity rather than for administrative or scientific coordination.

NIPH has built a network of 15 unique partners spanning 10 countries across just two projects, reflecting the international character of global health consortia where Southeast Asian implementation sites connect with European research institutions, NGOs, and diagnostics companies. Their network is geographically diverse, linking Cambodia to European-led health research infrastructures.

What sets them apart

NIPH is one of very few Southeast Asian public health institutions with direct H2020 participation, giving them rare credibility as a bridge between EU-funded research and real-world implementation in Cambodia — a country increasingly used as an evidence-generation site for global health interventions. For consortia targeting low-income country populations or needing regulatory-adjacent public health authority backing in the Mekong region, NIPH provides access that academic partners elsewhere cannot replicate. Their combination of public authority status and field implementation experience makes them particularly valuable for projects requiring community trust, facility access, and government-linked health data.

Highlights from their portfolio

• SCUBY
  The larger of the two projects (EUR 446,700), SCUBY addressed diabetes and hypertension scale-up for vulnerable Cambodians — a high-burden NCD challenge with direct relevance to health system strengthening in Southeast Asia.
• CHILI
  Running until 2026, CHILI is NIPH's most technically ambitious project, combining community HPV self-sampling with molecular diagnostics (proteomics, DNA genotyping) — rare capabilities for a public body in a low-income country context.